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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53 S27In this study, we evaluate the RNAi effect against MMP13 in preventing
cartilage degradation by directly injecting chemically modulated siR-
NAs to surgically induced murine OA knee joints. Our hypothesis was
that effective RNAi could be achieved by injection of highly concen-
trated siRNA in the knee joint, resulting in reduced development of
osteoarthritis.
Methods: Knee OAs were surgically induced to C57BL/6 mice by
destabilization of the medial meniscus (DMM) method, by trans-
ecting the medial meniscotibial ligament under general anesthesia.
To determine the timing of protease expressions in the murine DMM
induced OA model, messenger RNA (mRNA) of MMP13 from knee
cartilage were analyzed at 3 days, 1 week, 2 weeks, 4 weeks, and 6
weeks after surgery by quantitative polymerase chain reaction
(qPCR).
One week after DMM induction, chemically modulated siRNAs were
injected in the knee joint. Two different content of injection were
evaluated. Treatment groups consisted of a group which MMP13 siRNA
was injected, and another group in which control siRNA was injected.
The control siRNAwas conﬁrmed not to affect MMP13 in vitro. The RNAi
effects were assessed by quantifying MMP13 mRNA in knee cartilage at
48 hours after siRNA injection. Histological assessment of articular
cartilage at 8 weeks post DMM operation was conducted to assess the
effect of siRNA injection at one week after DMM in osteoarthritis
progression, according to the OARSI recommendation for OA knee
scoring in mice.
Results: Surgically induced OAs were successfully achieved in
the DMM model of mice. MMP13 expressions elevated from the
third post operative day, and peaked in a week after DMM surgery
(Fig. 1). Expression level of MMP13 mRNA was signiﬁcantly
decreased at 48 hours after injection of MMP13 siRNA to the knee
joint, compared to negative control siRNA injection (Fig. 2).
Signiﬁcant improvement was observed in the histological score of
MMP siRNA treated group, compared to the control siRNA injected
group.
Conclusions: Direct injection of siRNAs targeting MMP13 at the early
phase of OA development has the potential to inhibit protease expres-
sion and inhibits cartilage degradation in vivo.ĂĂ34
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Purpose: Compared to the original autologous cartilage transplantation
technique, matrix associated autologous cartilage transplantation
(MACT) techniques, as a possibility of cartilage repair technique, have
achieved comparable outcome at mid-term, but there is still a lack of
long-term results. The goal of this study was to obtain ﬁrst results after
10 years in a MACT technique in the knee.
Methods: A total number of 53 (22 female, 31 male) patients with
articular cartilage lesions of the knee were included in this prospective
case series. The average age ( SD) at implantation was 32  12 years
and the average Body Mass Index (BMI) was 24.5  3.8 kg/m2. The
average defect size was 4.4  1.9 cm2 (50 single defects, 3 patients with
multiple defects). All defects were classiﬁed as Outerbridge III or IV.
Primary indications (42 patients) were a stable joint, normal knee
alignment, isolated chondral defects with otherwise healthy adjacent
cartilage and age < 55 years. Secondary indications (11 patients) were
not fulﬁlling the primary indication criteria or were salvage procedures.
Four clinical scores (subjective IKDC knee form, Lysholm score, the
patient perception scale of the Cincinnati knee rating system, objective
IKDC knee form) were obtained for clinical evaluation. All patients were
treated with Hyalograft C.
Results: Altogether, 3 of 53 patients reached the 10-year follow up to
this day. In this study group, we depicted a signiﬁcant increase in the
Cincinnati patient perception scale when compared to pre surgery
scores(2.9 vs. 8.0; p<0.01). The 8-year follow up group showed
signiﬁcant differences in the Lysholm score (57.4 vs. 83.4; p<0.01), the
IKDC subjective score (49.3 vs. 67.8; p<0.05) and the Cincinnati
patient perception scale (2.1 vs. 7.4; p<0.01). Graft failure occurred in
3 of 42 patients with primary indications and 9 of 11 patients with
secondary indications. The difference was statistically signiﬁcant
(p<0.001).
Conclusions: Our data suggests, that the promising short-term results
were also found at mid- and long-term in younger patients (< 40 years)
with stable joints, normal knee alignment and single defects. In
contrast, salvage cases did not proﬁt from the treatment.
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A PHASE IIA CLINICAL STUDY OF TISSUEGENE-C (TG-C) IN PATIENTS
WITH OSTEOARTHRITIS
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Purpose: TG-C is a gene and cell therapy for osteoarthritis that employs
ex vivo gene delivery via a retrovirally transduced, established line of
chondrocytes that overexpress transforming growth factor-b1 (TGF-b1).
TG-C contains normal (hChonJ) and transduced (hChonJb#7) chon-
drocytes by the ratio of 3:1. The hChonJ cells are normal allogeneic
chondrocytes and the hChonJb#7 cells are chondrocytes transduced
with TGF-b1 gene-containing retroviral vector, and further treated with
gamma-ray irradiation to limit their survival for up to 2 weeks in
patients. The gamma-ray irradiation was designed to render them
incapable of cell division and therefore to eliminate any possibility of
these cells causing cancer. Phase I study has demonstrated that no
severe adverse events (SAEs) were observed and dose limiting toxicity
was not observed up to the dose level of 3x107 cells/knee.
Methods: In the current study, the randomized and single blind phase
IIa trials were conducted to determine both safety and efﬁcacy in
patients with knee osteoarthritis. Participants (n ¼ 27, 21 females and
6 males) with a conﬁrmed diagnosis of knee osteoarthritis by MRI
were randomized to either 0.6x107 cells/knee (low dose group, n ¼ 13,
mean age of 60.467.50 year) or 1.8x107 cells/knee (high dose group,
n ¼ 14, mean age of 58.29  6.94 year) of TG-C treatment. The
primary evaluation was International Knee Document Committee
(IKDC) which is comprised of three sub-scales: pain, sports activities,
and daily function. The secondary evaluations were Western-Ontario
and MacMaster University (WOMAC) score and 100 mm Visual
Analogue Scale (VAS). These parameters were evaluated at 12, 24 and
